口服普萘洛尔治疗眶周部增生期婴幼儿血管瘤

Oral propranolol in the management of periorbital proliferating phase infantile hemangioma

目的探讨口服普萘洛尔治疗眶周部增生期婴幼儿血管瘤的疗效及安全性。方法2009年9月至2010年lO月，临床治疗12例眶周部增生期婴幼儿血管瘤患儿，女9例，男3例，年龄1．5～8．5个月，平均3．3个月，采用VI服普萘洛尔治疗。服药剂量每日2mg／kg，分3次给药，治疗时间为4～4l周（平均16周），依据服药前后瘤体大小、颜色变化进行疗效评价，通过服药疗程及期间出现的并发症情况进行安全性评估。结果12例患儿中，9例服药后瘤体明显消退；2例瘤体生长明显受抑制；1例服药后，因药物不良反应而终止治疗。服药期间，除少数患儿出现轻度的心率、血压暂时性降低及胃返流外，未出现其他较为严重的并发症。结论口服普萘洛尔治疗眶周部增生期婴幼儿血管瘤安全有效，随着临床研究的不断深入，有望成为非手术治疗婴幼儿血管瘤的重要方法之一。

Objective To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma. Methods A retrospective review of patient medical records was performed. 12 patients （9 female, 3 male; 1.5-8.5 months, average 3.3 months） with periorbital proliferating phase infantile hemangioma underwent oral propranolol therapy. The dosage was slowly increased to 2 mg/kg daily in divided doses for a mean duration of 16 weeks （ range 4 weeks- 41 weeks）. Therapeutic outcomes and safety were established by evaluating colour, size of lesion, duration of treatment and side-effects of treatment before and after treatment. Results Of these, 9 had a signification reduction in colour and size of the lesions, 2 had no further growth. 1 is stopped therapy due to hypotension after drug administration, ll other patients, although mild adverse effects were noted, no symptoms were severe enough to discontinue treatment. Conclusions Propranolol appears to be a safe and effective treatment in the management of periorbital proliferating phase infantile hemangioma.